在免疫原性方面，候选疫苗对31种血清型细菌表现出调理吞噬活性(opsonophagocytic activity，OPA)免疫应答。然而，与Prevnar 20相比，在VAX-31高剂量下，20种血清型中有18种的平均OPA免疫应答更高。Vaxcyte announced that its experimental pneumococcal polysaccharide conjugate vaccine VAX-31 showed similar safety to pfizer's competitor product Prevnar 20 in phase 1/2 trials.
$Vaxcyte (PCVX.US)$ The stock price surged nearly 43% during the intraday session. The company announced on Tuesday that its experimental pneumococcal polysaccharide conjugate vaccine (PCV) VAX-31 showed similar safety to its competitor's product Prevnar 20 in Phase 1/2 trials. $Pfizer (PFE.US)$ Its subsidiary product Prevnar 20 showed similar safety to $Vaxcyte(PCVX.US)$.
In terms of immunogenicity, the candidate vaccine demonstrated opsonophagocytic activity (OPA) immune response against 31 serotypes of bacteria. However, when compared to Prevnar 20, VAX-31 showed higher average OPA immune response in 18 out of 20 serotypes, particularly at the high dose.
Based on these results, Vaxcyte plans to advance the most comprehensive PCV candidate VAX-31 into Phase 3 trials in adults. The key Phase 3 study is expected to start in mid-2025 and revenue data is planned to be obtained in 2025. The company anticipates initiating the remaining Phase 3 trials in 2025 and 2026 to prepare a marketing application for the candidate drug.
Vaxcyte(PCVX.US) announced on Tuesday that its experimental pneumococcal polysaccharide conjugate vaccine(PCV) VAX-31 showed similar safety to Pfizer(PFE.US)'s product Prevnar 20 in Phase 1/2 trials, after which its stock price rose by approximately 33% pre-market. However, Pfizer's stock price fell by 2% pre-market.
Editor/new
